MDGL
Madrigal Pharmaceuticals, Inc. [MDGL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MDGL Stock Summary
In the News
MDGL Financial details
Company Rating
-
Market Cap
4.97B
Income
-374.53M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
376
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-12.56
Forward P/E
-
PEG
-8.71
P/S
-
P/B
197.6
P/C
-
P/FCF
-15.49
Quick Ratio
2.33
Current Ratio
2.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-19.99
EPS next Y
-
EPS next Q
-
EPS this Y
14.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.37%
-
-
-
-
SMA20
-3.63%
SMA50
8.97%
SMA100
50.18%
Inst Own
-
Inst Trans
-
ROA
-147%
ROE
-296%
ROC
-2.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
119.76-322.67
52W High
+30.45%
52W Low
+252.99%
RSI
47
Rel Volume
0.46
Avg Volume
576.5K
Volume
266.11K
Perf Week
-0.9%
Perf Month
-4.55%
Perf Quarter
42.22%
Perf Half Y
23.26%
-
-
-
-
Beta
-0.437
-
-
Volatility
5.14%, 9.94%
Prev Close
-1.75%
Price
420.055
Change
-0.87%
Company Profile
- Volume Average 576.5K
- Market Capitalization 4.97B
- Employee 376
- CEO Mr. William J. Sibold
- Headquarters West Conshohocken,PA,US
- IPO Date 2007-02-06
-
Website
https://www.madrigalpharma.com 
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
